Wan Xiaotian, Zhang Yiwen, Nie Yueli, Zhang Keyong, Jin Ze, Zhang Zhikun, Gan Lu, Liu Xiyu, He Jian
State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, China.
Department of Science and Education, The First People's Hospital of Changde City, Changde, China.
Transl Cancer Res. 2023 Aug 31;12(8):2181-2196. doi: 10.21037/tcr-23-345. Epub 2023 Aug 28.
Transition metals are commonly used catalysts in bioorthogonal chemistry and have attracted extensive attention in biochemistry because of their efficient catalytic performance. In recent years, transition metal-mediated cycloaddition reactions, bond cleavage, and formation reactions are being actively explored for tumor treatment. However, the direct application of transition metals in complex biological environments has several problems, including poor solubility, toxicity, and easy inactivation. The combination of transition metals and nanomaterials can solve those problems by playing a bioorthogonal catalytic role in tumor treatment. In this review, we summarize some research on the application of transition metals modified by nanomaterials in tumor therapy and discuss the potential and challenges of transition metal-mediated bioorthogonal therapy in comprehensive tumor therapy.
English literature on transition metal in cancer treatment was searched in PubMed and Web of Science. The main search terms were "cancer treatment", "bioorthogonal reaction", "transition metal", "bioorthogonal catalysis", etc.
This review summarizes research on several major transition metals that can be used for bioorthogonal catalysis with the assistance of nanomaterials in anti-tumor therapy. In addition, bioorthogonal catalysis is a new supplement to antitumor therapy. We have compiled the potential challenges of the clinical application of transition metal-based nanocatalysts, which lays the foundation for future research related to medicinal chemistry and targeted cancer therapy.
Most of the transition metals still have a lot of room for exploration in cancer treatment research. We still need more research to confirm the feasibility of and clinical trials.
过渡金属是生物正交化学中常用的催化剂,因其高效的催化性能在生物化学领域备受关注。近年来,过渡金属介导的环加成反应、键断裂和形成反应正被积极探索用于肿瘤治疗。然而,过渡金属在复杂生物环境中的直接应用存在诸多问题,包括溶解性差、毒性以及易失活等。过渡金属与纳米材料的结合可通过在肿瘤治疗中发挥生物正交催化作用来解决这些问题。在本综述中,我们总结了一些关于纳米材料修饰的过渡金属在肿瘤治疗中应用的研究,并讨论了过渡金属介导的生物正交疗法在综合肿瘤治疗中的潜力和挑战。
在PubMed和Web of Science中检索关于过渡金属在癌症治疗方面的英文文献。主要检索词为“癌症治疗”“生物正交反应”“过渡金属”“生物正交催化”等。
本综述总结了几种主要过渡金属在纳米材料辅助下用于生物正交催化的抗肿瘤治疗研究。此外,生物正交催化是抗肿瘤治疗的一种新补充。我们梳理了基于过渡金属的纳米催化剂临床应用的潜在挑战,为未来与药物化学和靶向癌症治疗相关的研究奠定了基础。
大多数过渡金属在癌症治疗研究中仍有很大探索空间。我们仍需更多研究来证实其可行性并开展临床试验。